Mesoblast (ASX: MSB) — Perfil da empresa, notícias e dados financeiros
Mesoblast focuses on cell therapy products for various diseases, aiming to lead in developing innovative therapeutic solutions.
Mesoblast
Mesoblast is a biotechnology company that develops allogeneic cellular medicines based on its proprietary mesenchymal lineage cell therapy platform. The company focuses on developing cell-based treatments for severe inflammatory and cardiovascular conditions, including pediatric steroid-refractory acute graft-versus-host disease, chronic heart failure, end-stage ischemic heart failure, and chronic low back pain due to degenerative disc disease. Its platform utilizes culture-expanded mesenchymal lineage precursor and stem cells that modulate immune responses, suppress inflammation, and promote tissue repair. The company conducts clinical trials globally and maintains operational facilities across Australia, the United States, and Singapore.
Resumo
Operações
Produtos e/ou serviços de Mesoblast
- Pediatric Allogeneic Cell Therapy: Allogeneic mesenchymal stromal cell treatment designed for pediatric patients suffering from steroid-refractory acute graft-versus-host disease following bone marrow or hematopoietic stem cell transplantation. The therapy reduces systemic inflammation and promotes immune tolerance in pediatric populations.
- Adult Inflammatory Disease Cell Therapy: Intravenous mesenchymal lineage stem cell therapy evaluated in clinical studies for systemic inflammatory conditions, including severe acute respiratory distress syndrome caused by viral infections and biological treatment-resistant moderate-to-severe Crohn's disease.
- Advanced Heart Failure Therapy: Direct myocardial injection of allogeneic mesenchymal precursor cells targeting patients with chronic heart failure reduced ejection fraction and left ventricular assist device recipients, aiming to reduce recurrent cardiovascular hospitalizations and major adverse cardiac events.
- Degenerative Disc Disease Treatment: Direct intradiscal injection of allogeneic mesenchymal precursor cells combined with hyaluronic acid for patients with chronic low back pain caused by degenerative disc disease, focusing on long-term pain reduction and functional improvement.
- Allogeneic Cellular Manufacturing: Scalable industrial bioprocessing and cell culture manufacturing capabilities producing standardized, off-the-shelf mesenchymal lineage cell therapy products in bioreactor facilities under current Good Manufacturing Practice standards for global clinical supply.
- Cell Therapy Commercialization Partnerships: Strategic licensing, distribution, and commercial co-development agreements with global pharmaceutical companies to commercialize specialized cellular medicines across commercial markets in North America, Europe, and Asia-Pacific regions.
equipe executiva do Mesoblast
- Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
- Eric A. RoseChief Medical Officer & Executive Director
- Paul HughesGlobal Head of Corporate Communications & Joint Company Secretary
- Anthony WhealHead of Human Resources
- Paul J. SimmonsScientific Advisor to the Chief Executive Officer
- Geraldine StortonHead of Regulatory Affairs & Quality Management
- Daniel DevineHead of Special Projects
- Justin HorstHead of Manufacturing
- Fiona SeeSenior VP & Head of Translational Research
- Marcelo SantoroChief Commercial Officer
Últimas notícias sobre a Mesoblast
Mesoblast shares jump 19.7% on strong Ryoncil revenue
AustraliaMesoblast revenue grows 44% to US$28M
AustraliaMesoblast reaches target of 300 trial patients
AustraliaMesoblast delivers full year revenue of US$115M
AustraliaMesoblast acquires Mayo Clinic CAR-MSC technology licence
AustraliaFDA clears Mesoblast for pivotal DMD clinical trial
Australia
Comunicados recentes
O que a Mesoblast (MSB) comunicou ao mercado, do mais recente para o mais antigo.
- Annual Report to Shareholders
- Notice of Annual General Meeting and Proxy Form
- Appendix 4G and Corporate Governance Statement
- Ceasing to be a substantial holder
- Becoming a substantial holder
Histórico de dividendos
Dividendos por ação pagos pela Mesoblast, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | — | — | — | $0.0500 |
| FY2026 | — | — | — | $0.9600 |
| FY2025 | — | — | — | $7.2000 |
| FY2024 | — | — | — | $1.0100 |
| FY2023 | — | — | — | $0.8400 |
Principais indicadores financeiros
Resultados divulgados pela Mesoblast, em USD.
- Cap. de mercado
- 2,4 bi
- Receita (TTM)
- 120,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -47.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 122,9 mi | -52,4 mi | -58,8 mi | |
| 17,2 mi | -62,4 mi | -102,1 mi | |
| 5,9 mi | -84,1 mi | -88 mi | |
| 7,5 mi | -69,3 mi | -81,9 mi |